Compare Amylx Pharmaceuticals Inc (AMLX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Sirius XM Holdings Inc trades at $30.37 (market cap $10.24B). The key difference: Sirius XM Holdings Inc is far larger — about 5.2× Amylx Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 3.55% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SIRI | |
|---|---|---|
Market Cap | $1.98B | $10.24B |
Sector | Health | Media |
52-Week High | $18.70 | $30.75 |
52-Week Low | $7.64 | $19.92 |
Enterprise Value | $1.70B | $19.91B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SIRI trades at $30.42, down 0.88% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company shows solid fundamentals with a P/E of 12.89, P/B of 0.87, and consistent earnings beats in recent quarters. Recent developments include upcoming Q2 2026 results on July 30, 2026, and inclusion in the S&P MidCap 400 index.
Outlook remains positive with analyst consensus at Buy (58%) and a $31.17 price target. Key opportunities include strong cash flow and dividend yield, while risks involve competitive pressures and high debt levels. The stock offers value characteristics with upside potential near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
